|
Miraculins Inc., a biotechnology company dedicated to the discovery and development of diagnostic tools and therapeutic products for cancer, has closed its previously announced private placement (the "Offering") with aggregate gross proceeds to the Company of $625,064.70 from the sale of 4,167,098 units (the "Units") at a price of $0.15 per Unit.
Read More
|
|
Miraculins Inc., a biotechnology company dedicated to the discovery and development of diagnostic tools and therapeutic products for cancer, is pleased to announce that Stephan J. Frost, PhD, has been appointed Director, Research and Development.
Read More
|
|
Miraculins Inc., a biotechnology company dedicated to the discovery and development of diagnostic tools and therapeutic products for cancer, today announces a non-brokered private placement offering (the “Offering”) of up to 5,000,000 units (“Units”) at a price of $0.15 per Unit for gross proceeds of up to $750,000.
Read More
|
|
Miraculins Inc., a biotechnology company dedicated to the discovery and development of diagnostic tools and therapeutic products for cancer, is pleased to announce that it has reached an agreement with Diagnos Inc.(TSX-V:ADK), a leader in the use of artificial intelligence (AI) and advanced knowledge extraction techniques, to provide services towards the development of Miraculins’ cancer diagnostic discovery programs.
Read More
|
|
Miraculins Inc., a biotechnology company, dedicated to the discovery and development of diagnostic tools and therapeutic products for cancer, is pleased to announce that it is filing today, a pre-IDE (Investigational Device Exemption) submission with the U.S. Food and Drug Administration (FDA), in preparation for its planned clinical study for its P2V™ prostate cancer diagnostic test.
Read More
|
|
|